Neuralink
Neuralink is a neurotechnology company focused on developing implantable brain-computer interfaces (BCIs). Their technology aims to create a two-way communication pathway between the brain and external devices, potentially enabling individuals with paralysis to control computers and other devices with their thoughts.
The technology involves tiny, flexible threads with electrodes that are inserted into the brain to record neural activity and potentially stimulate neurons.
Seven Rivers Capital and its investors own Neuralink thru Investment Fund shares
Key Components and Technology:
- Implantable Chip: A coin-sized device is implanted in the skull.
- Flexible Threads: Ultra-thin threads with 1,024 electrodes are woven into the brain.
- Neural Recording and Stimulation: The electrodes record neural activity and can also stimulate neurons.
- Wireless Communication: The device wirelessly transmits data to an external device via Bluetooth.
- Surgical Robot: A specialized robot is used to precisely place the threads in the brain.
Potential Applications:
- Restoring Movement:The most immediate application is helping people with paralysis control prosthetics or exoskeletons with their thoughts.
- Treating Neurological Disorders:Addressing conditions like Parkinson’s disease, spinal cord injuries, and other neurological disorders.
- Enhancing Cognitive Abilities:Exploring potential for improving memory, learning, and other cognitive functions.
- Human-Computer Interaction:Facilitating new ways for humans to interact with technology.
Key distinctions from other BCIs:
- Higher Electrode Count:Neuralink’s device has a significantly larger number of electrodes compared to other BCIs, allowing for more detailed recording and control.
- Direct Neuron Connection:Neuralink’s technology targets individual neurons, providing more precise data for decoding brain signals.
Current status:
- Neuralink has conducted human trials, with the first patient reportedly able to control a computer mouse using their thoughts.
- The company is still in the early stages of development and faces ongoing challenges, including issues with electrode retraction in some patients.
